The PostEra crew (L-R); technology chief Matthew Robinson, CEO Aaron Morris and CSO Alpha Lee
January 7, 2025 11:10 AM EST
Deals
AI

Pfiz­er ex­tends AI drug dis­cov­ery pact with PostEra, adding AD­Cs to deal

Lei Lei Wu

News Reporter

Pfiz­er has re-upped its drug dis­cov­ery deal with AI start­up PostEra to de­vel­op small mol­e­cule drugs and new war­heads for an­ti­body-drug con­ju­gates, a ma­jor area …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

FDA says Ozem­pic, We­govy short­age is over

Kevin Tang's Con­cen­tra tries to dis­rupt pro­posed Ace­lyrin-Alu­mis merg­er

Pfiz­er ends roll­out of Be­qvez, putting an­oth­er dent in he­mo­phil­ia gene ther­a­py field

Mer­ck KGaA tees up changes to lead­er­ship team; Ex-CVS Health CEO joins Ther­mo Fish­er’s board

sponsored

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

A service from the Financial Times